Thermo Fisher Scientific Inc. $TMO Holdings Trimmed by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 887,598 shares of the medical research company’s stock after selling 186,072 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.24% of Thermo Fisher Scientific worth $599,270,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Bank OZK acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $1,096,000. Ausdal Financial Partners Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $456,000. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific in the second quarter worth $15,501,867,000. German American Bancorp Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $4,920,000. Finally, Parallax Volatility Advisers L.P. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $814,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing the prior authorization, which had $1 billion remaining. The program has no expiration date and could support per-share results and signal confidence in the business. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
• Positive Sentiment: Recent quarterly results were better than expected: EPS of $6.68 beat the $6.40 consensus, while revenue of $12.14 billion exceeded estimates and increased 9.1% year over year. Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
• Positive Sentiment: Thermo Fisher declared a quarterly dividend of $0.47 per share, payable January 15, 2027. The annualized dividend is $1.88 per share, though the indicated yield is modest at about 0.3%. Thermo Fisher Scientific Announces Quarterly Dividend
• Positive Sentiment: The company introduced value-priced AmpSure qPCR master mixes, adding an offering aimed at labs seeking dependable testing performance at lower cost. Thermo Fisher Introduces AmpSure Universal qPCR Master Mixes
• Neutral Sentiment: Market research reports point to growth in oligonucleotide synthesis, mRNA manufacturing, protein labeling and Q-TOF mass spectrometry—areas related to Thermo Fisher’s markets. These industry forecasts suggest potential demand tailwinds, but do not provide company-specific sales or earnings guidance. Global Oligonucleotide Synthesis Services Market Report 2026

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TMO. Scotiabank initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an “outperform” rating for the company. Wells Fargo & Company lowered Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. The Goldman Sachs Group increased their price target on shares of Thermo Fisher Scientific from $650.00 to $780.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $720.00 to $750.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Finally, Royal Bank Of Canada raised their target price on shares of Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $683.64.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 50,046 shares of company stock worth $30,779,192 over the last 90 days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.7%

NYSE TMO opened at $694.93 on Friday. The company has a 50 day moving average of $661.03 and a 200-day moving average of $554.78. The company has a market cap of $257.48 billion, a price-to-earnings ratio of 36.65, a PEG ratio of 2.83 and a beta of 0.84. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $712.17.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28. The company had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. Thermo Fisher Scientific’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm posted $5.79 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.92%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.

The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.